Market closed
Kairos Pharma Ltd./$KAPA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kairos Pharma Ltd.
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Ticker
$KAPA
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Employees
3
Website
KAPA Metrics
BasicAdvanced
$13M
-
-$0.23
-
-
Price and volume
Market cap
$13M
52-week high
$1.31
52-week low
$0.67
Average daily volume
137K
Financial strength
Current ratio
4.203
Quick ratio
1.282
Interest coverage (TTM)
-12.40%
Management effectiveness
Return on assets (TTM)
-43.50%
Return on equity (TTM)
-192.96%
Valuation
Price to book
2.17
Price to tangible book (TTM)
2.28
Price to free cash flow (TTM)
-2.168
Growth
Earnings per share change (TTM)
31.33%
3-year earnings per share growth (CAGR)
-0.74%
KAPA News
AllArticlesVideos
Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
Business Wire·2 weeks ago
Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer
Business Wire·3 weeks ago
Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kairos Pharma Ltd. stock?
Kairos Pharma Ltd. (KAPA) has a market cap of $13M as of May 09, 2025.
What is the P/E ratio for Kairos Pharma Ltd. stock?
The price to earnings (P/E) ratio for Kairos Pharma Ltd. (KAPA) stock is 0 as of May 09, 2025.
Does Kairos Pharma Ltd. stock pay dividends?
No, Kairos Pharma Ltd. (KAPA) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Kairos Pharma Ltd. dividend payment date?
Kairos Pharma Ltd. (KAPA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kairos Pharma Ltd.?
Kairos Pharma Ltd. (KAPA) does not currently have a Beta indicator.